Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F14%3A00061523" target="_blank" >RIV/00159816:_____/14:00061523 - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/14:E0103894

Result on the web

<a href="http://dx.doi.org/10.1016/S1474-4422(13)70308-9" target="_blank" >http://dx.doi.org/10.1016/S1474-4422(13)70308-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1474-4422(13)70308-9" target="_blank" >10.1016/S1474-4422(13)70308-9</a>

Result language

angličtina

Original language name

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Original language description

Background Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing remitting multiple sclerosis. We aimed to provide further evidence for the safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis. Methods This international, randomised, double-blind, placebo-controlled, phase 3 study enrolled adults aged 18-55 years with relapsing multiple sclerosis, one or more relapse in the previous 12 months or two or more in the previous 24 months but no relapse in the previous 30 days, and an Expanded Disability Status Scale (EDSS) score of 5.5 points or less. Patients were recruited from 189 sites in 26 countries and randomly assigned (1:1:1) to once-daily placebo, teriflunomide 7 mg, or teriflunomide 14 mg via an interactive voice recognition system. Treatment duration was variable, ending 48 weeks after the last patient was included. The primary endpoint was annualised relapse rate (number of relapses per patient-year) an

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet Neurology

ISSN

1474-4422

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

247-256

UT code for WoS article

000332264300008

EID of the result in the Scopus database

—